Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €5.70 EUR
Change Today 0.00 / 0.00%
Volume 3.2K
TXCL On Other Exchanges
Symbol
Exchange
EN Paris
Berlin
OTC US
As of 11:35 AM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

txcell (TXCL) Snapshot

Open
€5.79
Previous Close
€5.70
Day High
€5.79
Day Low
€5.69
52 Week High
06/2/14 - €8.10
52 Week Low
10/16/14 - €4.70
Market Cap
66.5M
Average Volume 10 Days
5.9K
EPS TTM
--
Shares Outstanding
11.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TXCELL (TXCL)

Related News

No related news articles were found.

txcell (TXCL) Related Businessweek News

No Related Businessweek News Found

txcell (TXCL) Details

TxCell Promesses develops cell-based immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases. The company’s product candidates include OvaSave, which has completed phase I/II clinical trials for the treatment of severe refractory Crohn’s disease; and Col-Treg, which is under preclinical stage for the treatment of autoimmune uveitis. Its other product candidates include Myelin that is under development for the treatment of central nervous system inflammatory diseases; and HSP60, which is under development for the treatment of autoimmune and inflammatory diseases. The company was formerly known as TxCell S.A. and changed its name to TxCell Promesses in April 2014. TxCell Promesses was founded in 2001 and is headquartered in Valbonne, France.

40 Employees
Last Reported Date: 10/2/14
Founded in 2001

txcell (TXCL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

txcell (TXCL) Key Developments

TxCell Promesses Presents at 27th Annual ROTH Conference, Mar-11-2015 09:30 AM

TxCell Promesses Presents at 27th Annual ROTH Conference, Mar-11-2015 09:30 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Damian Marron, Chief Executive Officer and Director.

TxCell Promesses Announces Revenue Results for the Fourth Quarter and Full Year of Fiscal 2014

TxCell Promesses announced revenue results for the fourth quarter and full year of fiscal 2014. For the year, the company generated revenues of EUR 1,327,000. For the quarter, the company generated revenues of EUR 1,083,000. This compares with a revenue of EUR 17,000 for the year 2013, recorded during the fourth quarter of 2013.

TxCell Promesses Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 04:50 PM

TxCell Promesses Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 04:50 PM. Venue: Metropolitan Club, One East 60th Street, New York, NY 10022, United States. Speakers: Damian Marron, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TXCL:FP €5.70 EUR 0.00

TXCL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TXCL.
View Industry Companies
 

Industry Analysis

TXCL

Industry Average

Valuation TXCL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.5x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TXCELL, please visit www.txcell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.